Fibrosis

Open Access  ISSN: 2959-605X (Online);  2959-6041 (Print)

Fibrosis aims to provide a unique forum through which the Fibrosis community will learn about the latest, most significant Fibrosis-related advances across the life, physical, applied and social sciences. Areas of interest include fundamental, preclinical research that furthers our understanding of the mechanisms underlying scar initiation, propagation and progression; work aiming to translate this knowledge to the clinic by focusing on new approaches for the development and delivery of diagnostic and therapeutic modalities; clinical studies informing Fibrosis diagnosis, treatment and prevention; and new ways of understanding the global societal impact of Fibrosis.

Editor-in-Chief

Guoying  Yu Prof. Guoying Yu
State Key Laboratory of Cell Differentiation and Regulation, College of Life Sciences, Henan Normal University, Xinxiang, China

Editorial Board

Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic interstitial lung disease with unknown etiology. Matrix metalloproteinases (MMPs) are in...

Hepatic stellate cells comprise a minor cell population in the liver that plays a key role in the pathogenesis of hepatic fibrosis. In chronic liver d...

Currently, low dose radiotherapy (LDRT) is being tested for treating life-threatening pneumonia in COVID-19 patients. Despite the debates over the c...

Hepatic stellate cells comprise a minor cell population in the liver that plays a key role in the pathogenesis of hepatic fibrosis. In chronic liver d...

Currently, low dose radiotherapy (LDRT) is being tested for treating life-threatening pneumonia in COVID-19 patients. Despite the debates over the c...

Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic interstitial lung disease with unknown etiology. Matrix metalloproteinases (MMPs) are in...